Staging of Dementia Severity With the Hong Kong Version of the Montreal Cognitive Assessment (HK-MoCA)'s
- PMID: 32701514
- DOI: 10.1097/WAD.0000000000000399
Staging of Dementia Severity With the Hong Kong Version of the Montreal Cognitive Assessment (HK-MoCA)'s
Abstract
Background: The Hong Kong version of Montreal Cognitive Assessment (HK-MoCA) has been used to screen for dementia, but it has not been validated to delineate the stages of Alzheimer disease (AD). This study aimed to determine the cut-off score ranges for mild, moderate, and severe AD.
Methods: The HK-MoCA score was matched against the Clinical Dementia Rating on 155 patients with AD. Investigators performing the HK-MoCA and Clinical Dementia Rating were blinded to each other. Receiver-operating characteristic analysis was used to determine the cut-off scores between different stages of AD (mild, moderate, and severe stage). A secondary analysis with adjustments for age and education received were also performed.
Result: The cut-off score in HK-MoCA was ≤4 for those with severe AD (sensitivity 84.4%, specificity 91.9%, area under curve=0.92, P<0.001) and 5 to 9 for those with moderate AD (sensitivity 86.3%, specificity of 93.3%, area under curve=0.953, P<0.001). With adjustments for age and education, the cut-off score for moderate AD was adjusted to 5 to 8, whereas the cut-off score for severe AD remained unchanged.
Conclusions: The severity of AD could be delineated using the HK-MoCA for the Cantonese-speaking population in Hong Kong, and the effect of education on the cut-off score needs further investigation.
References
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th Edition. Arlington, VA: American Psychiatric Association; 2013.
-
- McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–269.
-
- Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154–1166.
-
- National Institute for Health and Care Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. (Technology appraisal guidance - TA217); 2011. 2018. Available at: https://www.nice.org.uk/guidance/ta217. Accessed December 4, 2019.
-
- Olde Rikkert MGM, Tona KD, Janssen L, et al. Validity, reliability, and feasibility of clinical staging scales in dementia. Am J Alzheimers Dis Other Demen. 2011;26:357–365.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
